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Objective
The survival benefit of adjuvant radiotherapy and 5-fluorouracil
versus observation alone after surgery was investigated in
patients with pancreatic head and periampullary cancers.
Summary Background Data
A previous study of adjuvant radiotherapy and chemotherapy
in these cancers by the Gastrointestinal Tract Cancer Cooper-
ative Group of EORTC has been followed by other studies
with conflicting results.
Methods
Eligible patients with T1-2N0-1aM0 pancreatic head or T1-
3N0-1aM0 periampullary cancer and histologically proven ad-
enocarcinoma were randomized after resection.
Results
Between 1987 and 1995, 218 patients were randomized (108
patients in the observation group, 110 patients in the treat-
ment group). Eleven patients were ineligible (five in the obser-
vation group and six in the treatment group). Baseline charac-
teristics were comparable between the two groups. One
hundred fourteen patients (55%) had pancreatic cancer (54 in
the observation group and 60 in the treatment group). In the
treatment arm, 21 patients (20%) received no treatment be-
cause of postoperative complications or patient refusal. In the
treatment group, only minor toxicity was observed. The me-
dian duration of survival was 19.0 months for the observation
group and 24.5 months in the treatment group (log-rank, p 5
0.208). The 2-year survival estimates were 41% and 51%,
respectively. The results when stratifying for tumor location
showed a 2-year survival rate of 26% in the observation group
and 34% in the treatment group (log-rank, p 5 0.099) in pan-
creatic head cancer; in periampullary cancer, the 2-year sur-
vival rate was 63% in the observation group and 67% in the
treatment group (log-rank, p 5 0.737). No reduction of lo-
coregional recurrence rates was apparent in the groups.
Conclusions
Adjuvant radiotherapy in combination with 5-fluorouracil is
safe and well tolerated. However, the benefit in this study was
small; routine use of adjuvant chemoradiotherapy is not war-
ranted as standard treatment in cancer of the head of the
pancreas or periampullary region.
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The incidence of pancreatic cancer still seems to be
increasing, and it is the fifth most common cause of cancer
death in the United States. The prognosis is one of the most
dismal of all cancers: approximately 95% of all patients
diagnosed with pancreatic cancer will die within 1 year.1 To
date, the only potentially curative therapy is radical surgical
resection. After potentially curative resection for cancer of
the pancreatic head, the 1-year survival estimate is 50% to
60%, 2-year survival is 15% to 35%, and 5-year survival is
5% to 20%. In patients with periampullary carcinoma in the
ampulla of Vater, distal common bile duct, or duodenum, a
much better survival rate is obtained after surgical resection,
with a 5-year survival rate of 40% to 60%.2–7 After radical
resection, pancreatic cancer recurs primarily within the ab-
dominal cavity; most failures are locoregional and in the
liver. Distant metastases in the lung or peritoneal cavity are
seldom seen without local tumor recurrence and are char-
acteristic of late recurrence. Therefore, a treatment approach
combining local and systemic adjuvant treatment in pan-
creas and periampullary cancer seems interesting.
Radiation therapy with or without chemotherapy has been
extensively studied in locoregional advanced disease, espe-
cially the combination of external radiotherapy combined
with 5-fluorouracil (5-FU).8–11 The possible benefit of che-
moradiotherapy resulted in the use of radiotherapy com-
bined with 5-FU as adjuvant treatment in a prospective
randomized multicenter study performed by the Gastroin-
testinal Tumor Study Group (GITSG), in which 14 institutes
participated.12 The high incidence of pancreatic cancer and
the relatively large group of participating institutions was
intended to guarantee sufficient patient accrual. Radiother-
apy consisted of a split course of 40 Gy—two courses of 20
Gy with an interval of 2 weeks. 5-FU was given concomi-
tantly during the first week of radiotherapy and during 2
years thereafter. The 21 patients who received adjuvant
treatment had a 2-year survival rate of 43%, significantly
better than the 18% found in the control group (p , 0.03).
The trial was prematurely closed because the interim anal-
ysis showed a statistically significant difference in favor of
the treatment arm. Another 30 patients were treated with the
same adjuvant treatment and studied by the GITSG with
similar results (2-year survival rate 46%). This trial dem-
onstrated for the first time that prolonged survival could be
obtained with adjuvant treatment after surgical resection of
pancreatic cancer, although this was demonstrated in only a
small number of patients.13 However, a nonrandomized
study showed no significant difference in survival after
adjuvant treatment as given in the GITSG trial.14 At present,
no other prospective randomized trial in pancreatic or peri-
ampullary cancers has been reported in the United States or
Europe.
Recently, Yeo et al15 described the beneficial effect of
adjuvant radiotherapy and 5-FU treatment. However, in that
nonrandomized study, there seemed to be a selection of
patients. Patients who had a satisfactory recovery by post-
operative day 60 were encouraged to accept adjuvant ther-
apy. Patients declining radiotherapy were significantly older
and had a significantly longer postoperative stay, more
intensive care therapy, and a significantly greater incidence
of postoperative complications.
The GITSG trial led to the use of standard adjuvant
radiotherapy with 5-FU in the United States. In 1987, we
initiated a prospective randomized clinical trial in collabo-
ration with the European Organization for Research and
Treatment of Cancer (EORTC) to study the effect of adju-
vant radiotherapy and 5-FU.
METHODS
After resection for cancer of the head of the pancreas or
periampullary region (defined as tumors in the distal com-
mon bile duct, papilla of Vater, or duodenum), patients were
randomized and stratified for institution and tumor localiza-
tion (pancreatic head vs. periampullary) using the minimi-
zation technique.16 A Whipple procedure or pylorus-pre-
serving pancreatoduodenectomy was accepted as standard
resection (including total pancreatectomy). An extended
lymph node resection was not performed by the surgeons
participating in this study. TNM staging (according to the
UICC’s 1987 guidelines) was modified for N stage. N1a-
stage positive lymph nodes were located within the resec-
tion specimen, and N1b-stage positive lymph nodes were
located outside the resection area—for instance, retroperi-
toneally along the aorta. Eligible were patients with T1-
2N0-1aM0 pancreatic head cancer or T1-3N0-1aM0 peri-
ampullary cancer. Patients with stage T3 pancreatic head
cancer and stage T4 periampullary cancer were excluded
because of ingrowth into surrounding organs, with a limited
prognosis. Twenty-nine European institutes participated in
the study. Patients were randomized when the definitive
pathology report was available and the patient had recov-
ered from surgery. The treatment should start within 8
weeks after surgery; thus, patients with complications re-
sulting in a prolonged hospital stay were not randomized.
All the data were collected in a central database in the
EORTC Data Center, Brussels, Belgium. Central pathology
review was performed by one pathologist, who reviewed
slides of the specimen and compared them with the local
surgery and pathology reports.
The chemoradiotherapy regimen differed from that used
in the GITSG study. 5-FU was given during the periods of
radiotherapy, not thereafter, and was given as a continuous
infusion instead of a bolus injection. Radiotherapy was
given using a 3 or 4 field technique, starting 2 to 8 weeks
after surgery. The minimal and maximal doses in the target
volume were specified. Simulator films and computer plan-
ning were available for quality assurance. Doses in the liver,
kidneys, and spine were not to exceed the tolerance of these
normal tissues. Megavoltage photon irradiation of at least 6
MV energy was used. All fields were treated daily. The
absorbed daily dose was 2 Gy, 5 fractions a week, during 2
weeks. After an interval of 2 weeks, the treatment was
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repeated to a total absorbed dose of 40 Gy. Chemotherapy
was started on the same day before radiotherapy and con-
sisted of a 5-FU dose of 25 mg/kg per 24 hours, with a
maximal daily dose of 1500 mg. Depending on toxicity, the
second course consisted of 0, 3, or 5 days of 5-FU. No 5-FU
treatment during the second course of radiotherapy was
given in patients with grade 3 or 4 toxicity, 3 days of 5-FU
was given in patients with grade 1 or 2 toxicity, and 5 days
of 5-FU was given when no toxicity occurred. Toxicity was
scored according to the World Health Organization (WHO)
guidelines.
Assuming an overall 2-year survival rate of 30% in the
surgery-alone arm, a total of 110 deaths were necessary to
detect an absolute increase of 20% (i.e., to 50% 2-year
survival) on the adjuvant chemoradiotherapy arm, with a
two-sided type I error of 0.05 and a power of 80%.17 We
decided to randomize 100 patients on each treatment arm
and to perform the analysis when a total of 110 deaths were
registered. Safety analyses were based on all eligible pa-
tients who started their treatment. Efficacy analyses (sur-
vival, progression-free survival) were performed according
to the intention-to-treat principle. Survival curves were es-
timated using the Kaplan-Meier technique.18 Differences in
the duration of survival were compared using a two-sided
log-rank test at the 0.05 level of significance.19 The main
end point of the study was the duration of survival. The two
treatment arms were also compared for progression-free
survival and toxicity of treatment.
RESULTS
Patient Characteristics
Between September 1987 and April 1995, 218 patients
were randomized to the EORTC trial 40891, 108 patients in
the observation arm (Obs) and 110 patients in the chemo-
radiotherapy arm (Trt). Patients were recruited from 29
centers in Europe; 3 Dutch centers and 1 French center were
responsible for the randomization of 70% of all patients.
Five patients in the Obs group and 6 in the Trt group were
ineligible, resulting in 103 patients in the Obs group and 104
in the Trt group (Table 1). Baseline characteristics of eligi-
ble patients were comparable between the two study groups
(Table 2). Central pathology review was obtained in 178
patients; in 38 patients, only local pathology data were
present. From two patients, no additional data were avail-
able. After central pathology review, the diagnosis was
changed in four patients in the Obs group. Pancreatic head
cancer was incorrectly diagnosed in three patients, and one
patient’s diagnosis was changed from unknown to periam-
pullary cancer. In the Trt group, the diagnosis was changed
to pancreatic head cancer in five patients, including one
patient who had an unknown diagnosis after local pathology
analysis.
Treatment Data
Ten patients randomized in the Trt group (n 5 104)
refused to start treatment after randomization. In another 11
patients, problems developed after randomization that con-
traindicated adjuvant treatment. In one patient, long-lasting
septic shock developed as a result of leakage of the pancre-
aticojejunostomy; in four patients, rapid progression oc-
curred; one patient had only one functional kidney, located
within the radiation field; and another five patients had other
reasons not to start treatment, varying from the wrong
treatment arm to late lung embolism after discharge. In two
patients, no data at all could be obtained. As a result, a total
of 81 patients could be evaluated for treatment toxicity (50
patients with pancreatic head cancer and 31 patients with
periampullary cancer), and 207 patients for survival analy-
sis.
Chemoradiotherapy
Ninety-three percent of the treated patients received 40
Gy radiation therapy. Only one patient received one course
of radiation therapy (20 Gy) as a result of a persistent
duodenal ulcer; it was treated with antacids and histamine
blockers but did not heal after 6 weeks. As a result, the
second course was canceled. The total absorbed dose varied
between 30 and 43 Gy in another five patients because of
local practices in the radiation department where the patient
was treated.
The total dose of 5-FU was 6800 to 16,000 mg (median
12,000 mg). When corrected for body weight, the total dose
was 99 to 275 mg/kg (median 197 mg/kg). We considered
the maximal theoretical dose of 5-FU in the protocol to be
25 mg 3 body weight (kg) 3 9 days, taking into consider-
ation that a total daily dose should not exceed 1500 mg. The
maximal theoretical dose was 13,500 mg. The total dose of
5-FU given, expressed as a percentage of the maximal
theoretical dose, was 50% to 122% (median 90%).
Table 1. ELIGIBILITY OF RANDOMIZED
PATIENTS
Observation
(n 5 108)
Treatment
(n 5 110)
Eligible 103 104
Ineligible 5 6
No curative resection
(N1b)
3 2
Concurrent disease 0 1
Other cancer 0 0
T3 pancreas 2 3
Delay between surgery
and randomization
0 0
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Toxicity
Thirty-five patients (44%) received only 3 days of 5-FU
infusion during the second course of radiotherapy because
of grade 1 or 2 acute toxicity. No leukopenia or thrombope-
nia worse than WHO grade 1 was observed, and the daily
dose of 5-FU was never reduced. Minor toxicity was ob-
served in seven patients, with a maximal WHO grade 3
toxicity, especially nausea and vomiting. These toxicities
were always treated by conservative methods. Only one
instance of major toxicity was observed in the 81 patients
available for analysis; this patient was described above.
Progression-Free Survival
Of the 207 eligible patients, 68 (66%) in the Obs group
and 67 (65%) in the Trt group had progressive disease,
independent from the localization of the tumor. The site of
first progression and the site of distant progression are
shown in Table 3. In the 37 patients classified as “other,” 13
had peritoneal carcinomatosis, 5 had distant lymph node
metastases, and 19 had metastases varying from bone to
brain metastases, equally divided between the Obs and Trt
groups. There was no advantage of adjuvant treatment in
progression-free survival in the total group of eligible pa-
tients, nor in the patients with pancreatic head cancer, nor in
the patients with periampullary cancer, particularly not in
the locoregional recurrence rate. Median progression-free
survival was 16 months in the 103 patients in the Obs group
and 17.4 months in the 104 patients in the Trt group. The
2-year progression-free survival rates were 38% (95% CI,
28% to 48%) and 37% (95% CI, 27% to 47%), respectively
(p 5 0.643, relative risk 0.9 [95% CI, 0.7 to 1.3]).
Duration of Survival
In all randomized patients, the cause of death was ma-
lignant disease in 125 patients (68 Obs, 57 Trt), in-hospital
death in 3 patients (0 Obs, 3 Trt), nonmalignant/nontoxic
death in 8 patients (3 Obs, 5 Trt), and unknown in 8 patients
(5 Obs, 3 Trt). Survival was not influenced by treatment in
Table 3. PROGRESSION STATUS
(ALL ELIGIBLE PATIENTS)
Observation
(n 5 103)
Number (%)
Treatment
(n 5 104)
Number (%)
No documented progression 35 (34) 37 (36)
Documented progression 68 (66) 67 (65)
Site of first progression
Locoregional only* 15 15
Distant only 29 32
Both 22 19
Second malignancy 1 1
Unknown 1 0
Site of distant progression
Liver 34 34
Lung 7 5
Other 19 18
* Recurrence in resection area without distant metastases.
Table 2. CHARACTERISTICS OF ELIGIBLE
PATIENTS
Characteristic
Observation
(n 5 103)
Treatment
(n 5 104)
Median age (years) (range) 62 (39–80) 59 (24–78)
Median interval between surgery and
randomization (days) (range)
17 (1–57) 17 (6–57)
Number (%)
Sex Male 54 (52) 63 (61)
Female 49 (48) 41 (39)
Performance status 0 54 (52) 61 (59)
1 40 (39) 40 (39)
2 9 (9) 3 (3)
Jaundice Yes 62 (60) 68 (65)
No 39 (38) 36 (35)
Unknown 2 0
Surgical diagnosis Pancreatic head
cancer
57 (56) 55 (53)
Periampullary cancer 44 (42) 48 (46)
Unknown 2 1
Pathologic diagnosis* Pancreatic head
cancer
54 (53) 60 (58)
Periampullary cancer 48 (46) 44 (42)
Unknown 1 0
Primary tumor
Number 98 100
Largest dimension
(mm) (range)
24 (5–70) 20 (3–60)
T category T1 5 (11) 13 (26)
(pancreatic head) T2 36 (84) 33 (67)
T3 (ineligible) 2 (5) 3 (6)
T category T1 2 (5) 3 (9)
(periampullary T2 22 (55) 13 (37)
region) T3 16 (40) 19 (54)
Unknown 1 0
N category N0 19 (44) 26 (53)
(pancreatic head) N1a 23 (54) 23 (47)
N1b (ineligible) 1 (2) 0
N category N0 23 (56) 21 (60)
(periampullary N1a 16 (39) 14 (40)
region) N1b (ineligible) 2 (5) 0
Resection margin Positive 25 (24) 20 (19)
Negative 76 (75) 84 (81)
Unknown 2 0
Histopathologic Well differentiated 41 (40) 34 (33)
grading Moderately
differentiated
43 (42) 42 (40)
Poorly differentiated 18 (18) 28 (27)
Unknown 1 0
All M0.
* 178 patients central pathology review, 38 patients only local review. Treatment
groups were completely comparable without statistical difference.
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randomized patients or in eligible patients. Survival of all
eligible patients is shown in Figure 1. Median survival was
19 months in the Obs group and 24.5 months in the Trt
group; the 2-year survival rates were 41% (95% CI, 31% to
51%) in the Obs group and 51% (95% CI, 41% to 61%) in
the Trt group (p 5 0.208). The relative risk was 0.8 (95%
CI, 0.6 to 1.1). Taking into account the location of the
tumor, similar results were found. The survival data and
survival curves of the eligible patients in these two groups
are shown in Table 4 and in Figures 2 and 3. In the patients
with cancer of the head of the pancreas, a larger difference
was found, but again it was not significant. The median
duration of survival was 12.6 months in the Obs group and
17.1 months in the Trt group. Follow-up and number of
patients seem to be insufficient to draw conclusions, but a
trend in favor for adjuvant treatment was shown (p 5
0.099).
DISCUSSION
The prognosis of pancreatic cancer is dismal. Even if the
tumor is resectable, the incidence of locoregional recurrence
is high, up to 80%, and in most cases is combined with
distant metastases. Patients with periampullary carcinoma
have a more favorable outcome, with a 5-year survival rate
of 50% to 70%.2,4,6,7,20–22 To improve survival, several
therapeutic modalities have been used (intraoperative radio-
therapy, chemotherapy, and combinations of both) in pa-
tients with irresectable and resectable disease, with varying
success.8,10,11,14,23–29 The first study showing an effect of
adjuvant treatment in pancreatic cancer was the GITSG
trial.12 The 2-year survival rate after adjuvant treatment in
21 patients was 43%, significantly better than after surgery
alone (18%, p , 0.03). Another 30 patients were treated
with the same treatment regimen with comparable results.13
Because of the long accrual time and the small number of
patients entered in the GITSG study, we decided to assess
the possible value of radiotherapy and 5-FU as an adjuvant
to surgery in a larger group of patients. A prospective
Figure 1. Duration of survival in all eligible patients.
Table 4. SURVIVAL DATA BY TUMOR
AND TREATMENT ARM
Observation Treatment
Eligible Patients 103 104
Number of deaths 72* 63
Median duration of survival
(mos)
19.0 24.5
Survival estimates (95% CI)
2 years (%) 41 (31–51) 51 (41–61)
5 years (%) 22 (12–32) 28 (17–39)
Relative risk (95% CI) 1.0† 0.8 (0.6–1.1)
Log-rank p value 0.208
Pancreatic Head Cancer 54 60
Number of deaths 45 41
Median duration of survival
(mos)
12.6 17.1
Survival estimates (95% CI)
2 years (%) 23 (11–35) 37 (24–50)
5 years (%) 10 (0–20) 20 (5–35)
Relative risk (95% CI) 1.0† 0.7 (0.5–1.1)
Log-rank p value 0.099
Periampullary Cancer 49 44
Number of deaths 26 22
Median duration of survival
(mos)
40.1 39.5
Survival estimates (95% CI)
2 years (%) 64 (50–78) 70 (56–84)
5 years (%) 36 (20–52) 38 (21–55)
Relative risk (95% CI) 1.0† 0.91 (0.5–1.6)
Log-rank p value 0.737
* Tumor location was not confirmed for 1 patient.
† Reference category.
Figure 2. Duration of survival in eligible patients with pancreatic head
cancer.
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randomized trial was initiated in 1987 in collaboration with
the EORTC. The only treatment modification compared
with the GITSG trial was a reduction in 5-FU therapy: the
5-FU was limited to the first week of each radiation course.
A total of 218 patients with pancreatic head and periam-
pullary cancer were randomized in the study after resection.
Radiotherapy and 5-FU treatment did not induce major
toxicity (the worst WHO scale toxicity was 3); all patients
but the one with severe toxicity completed the treatment.
However, despite the success of this treatment in the only
other randomized study,12 no advantage in progression-free
survival or duration of overall survival was shown in this
large group of patients for either cancer. Nevertheless, the
difference in survival in patients with pancreatic head can-
cer seemed to be larger than in those with periampullary
cancer. The median duration of survival for patients with
pancreatic head cancer was 12.6 months in the Obs group
and 17.1 months in the Trt group (p 5 0.099). However, this
was an exploratory analysis: the sample size was not large
enough to draw any separate conclusions. Also, it should be
noted that N1a-stage patients were included in the trial. It is
questionable whether this variance from the GITSG study
makes any difference in outcome.
It is not likely that the difference in results from the
GITSG trial is due to the modification of the treatment
schedule. In pancreatic cancer, 5-FU alone is known to have
a limited effect, although this hypothesis cannot be proven
because of the different adjuvant treatment regimen used in
this study.30 Further, an advantage in survival would be
expected by the reduction of local recurrence, which was
not apparent in the study groups. The radiation dose of 40
Gy may not have been high enough to prevent local recur-
rence. This suggests that radiotherapy with 40 Gy does not
prevent local recurrence and hence is not effective as adju-
vant treatment in pancreatic or periampullary cancer. Be-
cause of the central review of pathology results, in almost
75% of cases there was no misdiagnosis in location or grade
of the tumor.
The question remains as to what kind of adjuvant therapy
should be proposed, given that surgery alone is inadequate.
Radiotherapy with chemotherapy has been applied as neo-
adjuvant treatment with some success, but the value of this
treatment is not yet proven.23,30–34 New chemotherapeutic
agents such as docetaxel, gemcitabine, and topotecan have
been studied, with response rates of 10% to 25%.35 Link et
al described a technique of intraarterial infusion chemother-
apy using the celiac axis after resection; they found prom-
ising results with respect to median survival, but only in 18
patients after curative resection.36–38
In summary, at present there seems to be no effective
adjuvant treatment available for patients with cancer of the
pancreas or periampullary region. Our results indicate that
there is no indication for radiotherapy and 5-FU as standard
adjuvant treatment after curative resection, although it can
be used safely and is well tolerated.
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Discussion
DR. J NEOPTOLEMOS (Liverpool, United Kingdom): This phase
III study of adjuvant chemoradiotherapy comprising 40 Gy of
postoperative external-beam radiotherapy with combined 5-FU is
the largest phase III adjuvant trial in pancreatic cancer and the
most important to date. The most widely quoted adjuvant trial was
undertaken by the Gastrointestinal Tumor Study Group, first pub-
lished in 1985 and subsequently published with additional fol-
low-up data along with an additional registration group in 1987.
On the basis of this study, along with questionable retrospective
nonrandomized and biased studies, a number of units, particularly
from North America, hold the firm opinion that adjuvant radio-
chemotherapy should be regarded as standard therapy following
resection for pancreatic ductal adenocarcinoma. The Gastrointes-
tinal Tumor Study Group (GITSG) included a total of only 43
patients in their randomized controlled study. The regimen com-
prised 40 Gy of postoperative external-beam radiochemotherapy,
with 5-FU given on the first 3 days of each 2-week 20-Gy fraction.
This was then followed by intravenous bolus 5-FU weekly for 2
years, or until relapse. The 5-year survival rate in the treatment
group was 18% versus 8% for the control group. The major
problem with this trial was that far too few patients were entered
into the study. Moreover, it took more than 8 years to complete
through many institutions around the United States. The average
recruitment per institution was less than 1 patient per year. The
confidence intervals of the study were so large that they would
easily overlap with many other studies in terms of 5-year survival
rate in which no adjuvant treatment had been given. Because of
serious doubts as to the statistical validity of this study, a further
30 patients were treated according to the study protocol, achieving
a similar result. Unfortunately, this additional study could not
retrieve the deficiencies of the original GITSG study.
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There is a second randomized controlled trial from Norway
which is not often referred to. In this study, a total of 43 patients
with ductal adenocarcinoma were randomized to adjuvant treat-
ment or to observation. Treatment comprised combination chemo-
therapy of 5-FU, doxorubicin, and mitomycin C. The treatment
group survived significantly longer (23 months) versus the control
group (11 months). Unfortunately, there was no improvement in
5-year survival, being 4% in the treatment arm and 8% in the
control group. The toxicity of the combination chemotherapy
treatment used in the study was so substantial that it would be
difficult to advise its use on a routine basis, particularly given the
lack of any longer-term survival.
Thus, the study organized by the EORTC is of enormous im-
portance. Most of the patients were recruited from Holland, but
other participating units were drawn from France, Belgium, Ger-
many, Portugal, and Italy. Analysis was by intention-to-treat.
Overall, the study did not reveal any statistically significant dif-
ferences in long-term survival. Taken at face value, this study
supports the notion that adjuvant treatment following resection for
pancreatic ductal adenocarcinoma is of no value.
There are two important points to be made about this study.
Firstly, unlike the GITSG trial, radiochemotherapy was given
without continuing 5-FU on a weekly basis—in other words, 5-FU
was only given during the course of radiotherapy. Thus, the benefit
that was observed in the GITSG study, apart from there being a
statistical type 2 error, could have been due to the follow-up
chemotherapy comprising weekly 5-FU bolus injections. Sec-
ondly, it is possible that the EORTC study is also underpowered.
In the observation arm, of 108 patients randomized, only 103 were
eligible. Of these, 54 had pancreatic ductal adenocarcinoma, 48
had ampullary cancer, and 1 was of unknown status. The problem
arises in the comparative treatment arm. Of 110 patients random-
ized to the treatment arm, 104 were eligible. Unfortunately, 10
patients refused and 11 did not start the treatment, and on 2
patients there were no data. This leaves only 81 patients. The
paper, however, identifies 60 patients with pancreatic ductal ade-
nocarcinoma and 44 patients with ampullary cancer that were
eligible for treatment initially without the exclusions. Unfortu-
nately, we are given no information as to the distribution of these
patients to the two arms. If we assume that the 23 patients who did
not receive treatment were equally distributed between the two
histological types, then less than 50 patients with pancreatic ductal
adenocarcinoma actually received the treatment.
Power calculations are as follows. To detect 20% differences
from a standard survival of 30% would require a minimum of 55
patients in each treatment group using 5% significance at 80%
power. In fact, 55 patients in each treatment group will allow a
detection of 20% differences from a standard survival ranging
from 20% to 40%, but always at 80% power. At 90% power, a
minimum of 73 patients in each group would be required. Al-
though there were 60 patients with pancreatic ductal adenocarci-
noma, because there was a large dropout rate, the sample size is
likely to be too small. The results seem inconclusive and may
mirror an inadequate sample size. The confidence interval of the
response rates spans from 0.5% to 1.1%, and yet this small sample
achieves borderline significance (log-rank 5 0.099). This suggests
that there is evidence of a treatment difference which may have
reached statistical significance with an increased number of pa-
tients.
At the present time, we are also seeing the final recruitment
phase for the European Study Group for Pancreatic Cancer Trial 1
(ESPAC-1). This study randomizes patients with pancreatic ductal
adenocarcinoma into four groups, as follows: a treatment arm
comprising radiochemotherapy followed by weekly 5-FU and fo-
linic acid for 6 months; the second group comprises radiochemo-
therapy as undertaken in the EORTC study; the third group com-
prises chemotherapy only, comprising 5-FU and folinic acid given
weekly for 6 months; the final and fourth group is an observation
arm.
The trial, which is the largest trial in pancreatic cancer to date,
has recruited nearly 550 patients from specialist units around
Europe. This trial should answer several important questions.
Firstly, whether adjuvant treatment using conventional approaches
is better than observation. Secondly, it will answer the question as
to which approach is superior compared to others. For example,
radiochemotherapy without follow-on chemotherapy is a relatively
short course of treatment and would obviously be attractive. Che-
motherapy alone for 6 months has the attraction that radiotherapy,
with its own set of toxicities, could be avoided. Finally, it may be
that the only effective adjuvant treatment is one which combines
radiochemotherapy and follow-on chemotherapy. As a precursor to
the ESPAC trial, the UK Pancreatic Cancer Group (UKPACA)
organized a study along the lines of the GITSG as a phase II study
and confirmed that toxicity was acceptable.
Dr. J. Klinkenbijl and colleagues from the EORTC are to be
congratulated for taking forward the clinical science of the treat-
ment of pancreatic cancer. The results of the ESPAC trial, with
recruitment due to close at the end of 1999, could be combined
with those of EORTC to provide a metaanalysis as additional
support for the results of the ESPAC trial one way or the other.
Further progress in the management of pancreatic cancer re-
quires many more trials similar to that organized by the EORTC,
which are randomized and undertaken to the high qualities set by
this study.
DR. J. KLINKENBIJL (Arnhem, The Netherlands): Thank you very
much for your comment. Of course we could have continued, but
we made very strict end points for the study beforehand, and there
were 50% of deaths in the treated group of patients when we
stopped the study. This was our cutoff point. Another fact was that
in the treatment group, especially in the pancreatic head cancer
treatment group, there were no survivors anymore. This would not
change by continuing, so the difference would not be greater at 2
years, 4 years, or 5 years. If we were to wait in the observation
group, the difference would only be smaller after a longer fol-
low-up period.
DR. NEOPTOLEMOS: Why did you not continue to recruit patients?
DR. KLINKENBIJL: The reason was that we had a cutoff point at
the death of half of the patients in the follow-up group. At the time
when we did the interim analysis, this point was achieved, so we
stopped the intake of patients. Afterwards, we can suggest that
maybe another 50 or 60 patients might have made a significant
difference, but I do not think so. All the treated patients had died,
but not the observed patients, so this is only speculation. I do not
know. Maybe your results are going to be better.
PROF. E. FARTHMANN (Freiburg, Germany): I too want to con-
gratulate the authors on the important study and the nice presen-
tation, and I thank you for giving me the manuscript beforehand to
go through it. I have prepared a slide as well to put this study into
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the context of the other studies that have been mentioned already.
This is the second prospective randomized study that has been
performed. The GITSG study has been mentioned already. As we
have heard, they did find a significant difference in a small number
of patients. Besides the Johns Hopkins study, which is retrospec-
tive, there is another retrospective one, not randomized, from
Milwaukee. So we have to go by the first two studies, and we are
eagerly awaiting the results of the still-running ESPAC-1 trial.
So what have we learned? We know from your study that this
treatment is well tolerated. It can be applied to a large population.
My point of criticism has been mentioned already. I think it is very
difficult to evaluate this form of treatment if we do not separate
pancreatic head carcinoma and periampullary tumors. We have
heard why this is necessary, and I think this should be done in
further studies. Nevertheless, you have demonstrated that locore-
gional recurrences were not different between the observation and
the treatment group, and since the lymph node stage and the rate
of positive resection margins were even slightly higher in the
observation group, I think these data are quite hard, although
unexpected. However, from your manuscript, I concluded that with
respect to grading, the treatment group was worse. There were
27% poorly differentiated versus 18%. This would be my first
question. Might this have influenced the results at all? Then you
showed a small benefit towards survival, and I think your intent-
to-treat analysis is perfectly correct. However, if this survival
analysis were based on all eligible patients who really started their
treatment, could you speculate that this difference might have
reached statistical significance? One more point: 80% of your
patients with pancreatic cancer had tumor extending beyond the
pancreas. These were formerly T2 tumors, and now they are T3
tumors, right? However, only 50% were classified as node-posi-
tive. This is a little bit surprising because we would expect a rate
of somewhere between 70% or 90% of lymph node-positive pa-
tients if they have an involved resection margin. Therefore, my
question: was the extent of lymphadenectomy controlled in any
way?
DR. KLINKENBIJL: No, it was not.
PROF. FARTHMANN: And finally, to look to the future and to a
future trial, if you were to start a new one, would you suggest
changing the medication, or would you consider switching to
neoadjuvant treatment, which is what we are doing right now?
DR. KLINKENBIJL: I completely agree that after doing the trial, it
would have been nicer, and I think better, to include only pancre-
atic head cancer, but as you could see on the slides, a number of
patients were switched from a diagnosis of periampullary to pan-
creatic head, and so on. Because there is a slight bias in this patient
group, I think you have to include the periampullary group. The
differentiation grade in the treatment group of the pancreatic head
cancer was worse in the periampullary than the observation group.
Maybe that is the reason why the results are not different, but we
did not look separately for that. When we looked at all the patients
with the intention-to-treat, and we did perform that analysis, there
was no difference in survival. It does not matter if it was a p value
of 0.1; it was not significant at all.
Standardized lymph node dissection was not performed. It was
only a normal Whipple or normal PPPD procedure, without an
extended lymph node dissection. If I get the opportunity to par-
ticipate in a new study, I would suggest performing neoadjuvant
chemoradiotherapy. I think that is the best way to try to get better
results.
PROF. H. BEGER (Ulm, Germany): This is surely a very important
step forward in our knowledge in terms of the treatment of ductal
pancreatic cancer. I have two questions. In terms of recurrence, we
have to discriminate between liver metastases, local lymph node,
peritoneal, and the pancreatic bed recurrence. Did you discriminate
in your follow-up for the type of recurrence? Because the patient
had a local lymph node dissection, not an extended lymph node
dissection, it might be important for the interpretation of your
results to have knowledge of the type of local and/or peritoneal
recurrence. The tendency is quite impressive in terms of the
difference in the outcome of the patients in the treatment group.
Secondly, if you add the micrometastases, almost 100% of the
patients have a metastatic state in ductal pancreatic cancer. My
question is directed to the doses you have applied. What about the
doses of the local radiation? Most of the studies, for example the
GITS group, used 56 Gy applied locally, and this maybe opened an
opportunity to improve the results by reduction or prevention of
local recurrence.
DR. KLINKENBIJL (Closing Discussion): The local recurrences
were only diagnosed with CT scanning, ultrasound, etc. There was
no histological proof, but the local recurrences are reliably seen on
the CT scan on the place of the pancreatic head. Everything outside
of that little block of tissue was mentioned as distant metastases.
Also, lymph nodes along the aorta, in the hepatoduodenal liga-
ment, and secondaries in the liver are staged as distant metastases.
It is possible that the 56 Gy in the earlier studies could enhance
a little the survival, but would have more effect on local recur-
rence. However, the toxicity of that dose is greater and more
severe than the 40 Gy. Maybe intraoperative radiotherapy is an
option. A lot of studies have been undertaken, but it is very
difficult to perform, and not all centers have this opportunity. I
think the neoadjuvant regimen is more and more going to be the
solution for this.
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